Abstract | PURPOSE: DESIGN: RESULTS: Thirty-two patients were enrolled; 16 to bevacizumab alone (Arm A) and 16 to bevacizumab plus docetaxel (Arm B). Toxicities were greater in Arm B with the most common grade 3/4 nonhematologic toxicities including fatigue, diarrhea, dehydration, and anorexia. No confirmed objective responses were observed. At 4 months, 2 of the 16 patients in Arm A and 3 of the 16 patients in Arm B were free from progression. The study was stopped according to the early stopping rule for futility. Median progression-free survival and overall survival were 43 days and 165 days in Arm A and 48 days and 125 days in Arm B. Elevated d-dimer levels and thrombin- antithrombin complexes were associated with decreased survival and increased toxicity. CONCLUSION:
|
Authors | Igor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, Barbara A Burtness, Jonathan D Cheng, Sue McLaughlin, André Rogatko, Zhiheng Xu, James C Watson, Louis M Weiner, Steven J Cohen |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 34
Issue 1
Pg. 70-5
(Feb 2011)
ISSN: 1537-453X [Electronic] United States |
PMID | 20458210
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Biomarkers
- Blood Coagulation Factors
- Deoxycytidine
- Bevacizumab
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, metabolism, secondary)
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
- Biomarkers
(metabolism)
- Blood Coagulation Factors
(metabolism)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Humans
- Liver Neoplasms
(drug therapy, metabolism, secondary)
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, metabolism, pathology)
- Neoplasm Staging
- Pancreatic Neoplasms
(drug therapy, metabolism, pathology)
- Peritoneal Neoplasms
(drug therapy, metabolism, secondary)
- Survival Rate
- Treatment Outcome
- Gemcitabine
|